Milrinone suppliers
Milrinone
- CAS:
- 78415-72-2
- MF:
- C12H9N3O
- MW:
- 211.22
Suppliers by country/region
Company Type
Properties
- Melting point:
- >3000C
- Boiling point:
- 350.9°C (rough estimate)
- Density
- 1.1922 (rough estimate)
- refractive index
- 1.5700 (estimate)
- storage temp.
- 2-8°C
- solubility
- DMSO: >10 mg/mL
- pka
- 7.21±0.10(Predicted)
- form
- powder
- color
- off-white
- Water Solubility
- Soluble in DMSO. Insoluble in water.
- Merck
- 14,6197
- Stability:
- Stable. Incompatible with strong oxidizing agents.
- InChIKey
- FYEJSUDMDUIMKJ-UHFFFAOYSA-N
Safety Information
- Symbol(GHS)
GHS06
- Signal word
- Danger
- Hazard statements
- H301
- Precautionary statements
- P301+P330+P331+P310
- Hazard Codes
- T,T+
- Risk Statements
- 23/24/25-26/27/28
- Safety Statements
- 36/37/39-45-22
- RIDADR
- UN 2811 6.1/PG 3
- WGK Germany
- 3
- RTECS
- DW1762000
- HazardClass
- 6.1(b)
- PackingGroup
- III
- HS Code
- 29337900
Use
Milrinone is non-digitalis, non-catecholamines cardiac drug , it is representative drug of phosphodiesterase inhibitor,selectively inhibiting phosphodiesterase in myocardial cells, increasing intracellular cyclic adenosine monophosphate, alter intracellular calcium transport, thereby increasing myocardial contractility and expanding peripheral vessel . An increase in myocardial oxygen consumption caused by Milrinone increasing myocardial contractility may be offset by its vasodilator effect. Milrinone is an ideal drug for the treatment of coronary artery stenosis, decompensated heart failure led by myocardial ischemia . Because milrinone hasβ receptor down features, it is an ideal drug for the treatment of decompensated heart failure in patients applying β-blocker . Because milrinone has effect on expanding small arteries and veins, it is more beneficial than dobutamine for the traetment of decompensated heart failure with severe pulmonary hypertension .
370 supplier list of "Milrinone"